% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
\PassOptionsToPackage{dvipsnames,svgnames*,x11names*}{xcolor}
%
\documentclass[
  12pt,
]{memoir}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  pdftitle={Medicine},
  pdfauthor={Susmit},
  colorlinks=true,
  linkcolor=blue,
  filecolor=Maroon,
  citecolor=Blue,
  urlcolor=red,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\usepackage[margin=2cm]{geometry}
\usepackage{graphicx}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{-\maxdimen} % remove section numbering

\title{Medicine}
\author{Susmit}
\date{2022-07-02}

\begin{document}
\frontmatter
\maketitle

\mainmatter
\openany
\raggedbottom
\twocoltocetc
\tableofcontents

\pagebreak

\hypertarget{cardiology}{%
\chapter{Cardiology}\label{cardiology}}

\hypertarget{presenting-problems-in-cvs-disease}{%
\section{Presenting problems in CVS
disease}\label{presenting-problems-in-cvs-disease}}

\hypertarget{features-of-benign-murmur}{%
\subsection{Features of benign murmur}\label{features-of-benign-murmur}}

\begin{itemize}
\tightlist
\item
  Soft
\item
  Midsystolic
\item
  Heard at left sternal edge
\item
  No radiation
\item
  No other cardiac abnormalities
\end{itemize}

\hypertarget{ecg}{%
\section{ECG}\label{ecg}}

\hypertarget{anatomy-of-an-ecg}{%
\subsection{Anatomy of an ECG}\label{anatomy-of-an-ecg}}

\includegraphics[width=0.7\textwidth]{../assets/ecg-anatomy.jpg}

\hypertarget{abnormalities-of-components}{%
\subsection{Abnormalities of
components}\label{abnormalities-of-components}}

\hypertarget{pathological-q}{%
\subsubsection{Pathological Q}\label{pathological-q}}

\begin{itemize}
\tightlist
\item
  Depth \textgreater{} 2mm
\item
  Height \textgreater{} 1mm
\item
  Present in \(\ge\) 2 leads
\item
  Assocd with loss of R height (Q \textgreater{} R/4; normally Q \(\le\)
  R/4)
\item
  \textbf{Indicates \emph{transmural} myocardial necrosis}
\end{itemize}

\hypertarget{segments-vs-intervals}{%
\subsubsection{Segments vs intervals}\label{segments-vs-intervals}}

\begin{itemize}
\tightlist
\item
  e.g.~ST segment = end of S \(\rightarrow\) start of T
\item
  PR interval = start of P \(\rightarrow\) start of R
\end{itemize}

\hypertarget{st-segment-elevation}{%
\subsubsection{ST segment elevation}\label{st-segment-elevation}}

\begin{itemize}
\tightlist
\item
  Normal: upto 1mm in limb leads, upto 2mm in chest leads
\item
  \textbf{Causes}

  \begin{itemize}
  \tightlist
  \item
    \textbf{STEMI:} \textbf{convexity} upwards
  \item
    \textbf{Acute periCArditis:}: \textbf{conCAvity} upwards
  \end{itemize}
\item
  \textbf{Indicates ongoing myocardial injury}
\end{itemize}

\hypertarget{myocardial-infarction}{%
\subsection{Myocardial infarction}\label{myocardial-infarction}}

\href{https://www.cvphysiology.com/CAD/CAD012}{A somewhat interesting
physiological explanation on how the changes arise}

\hypertarget{sites-of-infarction-based-on-lead}{%
\subsubsection{Sites of infarction based on
lead}\label{sites-of-infarction-based-on-lead}}

\begin{itemize}
\tightlist
\item
  Septal: V\(_1\), V\(_2\)
\item
  Anterior: V\(_3\), V\(_4\)
\item
  Lateral: I, aVL, V\(_5\), V\(_6\)
\item
  Extensive anterior: V\(_1\)-V\(_6\)
\item
  Anterolateral: I, aVL, V\(_1\)-V\(_6\)
\end{itemize}

\hypertarget{reciprocal-changes}{%
\subsubsection{Reciprocal changes}\label{reciprocal-changes}}

\begin{itemize}
\tightlist
\item
  Acute STEMI in some surface of the heart \(\rightarrow\) ST elevation
  in corresponding leads, and ST depression in reciprocal leads
\end{itemize}

\includegraphics[width=.7\textwidth]{../assets/reciprocal-leads.jpg}

\hypertarget{basic-pathophys-of-stemi}{%
\subsubsection{Basic pathophys of
STEMI}\label{basic-pathophys-of-stemi}}

\begin{itemize}
\tightlist
\item
  Occurs due to proximal \textbf{complete occlusion of major coronary
  artery}
\end{itemize}

\includegraphics[width=.5\textwidth]{../assets/STEMI.jpg}

\[
\begin{aligned}
&\fbox{A. Before the onset of infarction}\\
&\downarrow\\
&\fbox{B. In acute phase, ST elevation}\\
&\downarrow\\
&\fbox{C. Progressive loss of R and deepening Q}\\
&\downarrow\\
&\fbox{D. Resolution of ST elevation; fully developed pathological Q;
T inversion}\\
&\downarrow\\
&\fbox{E. In old infarcts, T-wave inversion may or may not persist}\\
\end{aligned}
\]

\begin{itemize}
\tightlist
\item
  ST elevation resolves after a few days
\end{itemize}

\pagebreak

\hypertarget{nstemi}{%
\subsubsection{NSTEMI}\label{nstemi}}

\begin{itemize}
\tightlist
\item
  \textbf{Partial occlusion of major} or \textbf{complete occlusion of
  minor} coronary artery
\item
  \emph{Subendocardial/partial-thickness MI} \(\rightarrow\) \textbf{no
  pathological Q}
\item
  \textbf{ST depression} + \textbf{T inversion} in chest leads
\end{itemize}

\hypertarget{coronary-artery-disease}{%
\section{Coronary Artery Disease}\label{coronary-artery-disease}}

\begin{itemize}
\tightlist
\item
  Diseases arising due to narrowing of the lumen of one or more coronary
  arteries and the resulting ischaemia/infarction of the myocardium or
  the conductive system.
\item
  \textbf{Types}:

  \begin{itemize}
  \tightlist
  \item
    Stable angina: Fixed atheromatous stenosis
  \item
    Unstable angina:

    \begin{itemize}
    \tightlist
    \item
      dynamic obstruction
    \item
      due to plaque rupture/erosion with thrombosis
    \end{itemize}
  \item
    MI
  \item
    Heart failure
  \item
    Arrhythmia
  \item
    Sudden cardiac death

    \begin{itemize}
    \tightlist
    \item
      ventricular arrhythmia
    \item
      asystole
    \item
      massive MI
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{arrhythmias}{%
\section{Arrhythmias}\label{arrhythmias}}

\hypertarget{classification-according-to-ecg-morphology}{%
\subsection{Classification according to ECG
morphology}\label{classification-according-to-ecg-morphology}}

\begin{itemize}
\tightlist
\item
  \textbf{Narrow complex}: QRS \textless{} 120ms (3 small sqs)

  \begin{itemize}
  \tightlist
  \item
    Sinus tachycardia
  \item
    Atrial fibrillation (irregular narrow complex tachycardia)
  \item
    Atrial flutter
  \item
    AV Nodal Re-entry Tachycardia (AVNRT aka SVT)
  \end{itemize}
\item
  \textbf{Broad complex}: QRS \textgreater{} 120ms (3 small sqs)

  \begin{itemize}
  \tightlist
  \item
    Ventricular tachycardia
  \item
    AV Re-entry Tachycardia (AVRT e.g.~Wolff-Parkinson-White syndrome)

    \begin{itemize}
    \tightlist
    \item
      Abnormal band of conductive tissue connecting atria and ventricles
      (accessory pathway)
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{management-of-svt}{%
\subsection{Management of SVT}\label{management-of-svt}}

\begin{itemize}
\tightlist
\item
  Carotid sinus massage or
\item
  Valsalva manoeuvre
\item
  If the manoeuvre fails,

  \begin{itemize}
  \tightlist
  \item
    Adenosine (3-12mg IV) or
  \item
    Rate-limiting CCB (Verapamil 5mg IV) or
  \item
    \(\beta\)-blocker
  \end{itemize}
\item
  If haemodynamic state compromised, DC cardioversion
\item
  Recurrent SVT \(\rightarrow\) catheter ablation
\end{itemize}

\hypertarget{atrial-fibrillation}{%
\section{Atrial fibrillation}\label{atrial-fibrillation}}

\hypertarget{causes}{%
\subsection{Causes}\label{causes}}

\begin{itemize}
\tightlist
\item
  \textbf{Cardiac}

  \begin{itemize}
  \tightlist
  \item
    CAD (including acute MI)
  \item
    Mitral stenosis (MS; rheumatic mitral valve disease)
  \item
    Hypertension
  \item
    Cardiomyopathy
  \end{itemize}
\item
  \textbf{Non-cardiac}

  \begin{itemize}
  \tightlist
  \item
    Thyrotoxicosis
  \item
    Pulmonary embolism
  \item
    Pneumonia
  \item
    Alcoholism
  \end{itemize}
\end{itemize}

\hypertarget{investigations}{%
\subsection{Investigations}\label{investigations}}

\begin{itemize}
\tightlist
\item
  ECG
\item
  Echo: to see valvular condition
\item
  Thyroid function test: to exclude thyrotoxicosis
\end{itemize}

\hypertarget{management-of-af}{%
\subsection{Management of AF}\label{management-of-af}}

\begin{itemize}
\tightlist
\item
  \textbf{Rhythm control}:

  \begin{itemize}
  \tightlist
  \item
    Pharmacological cardioversion

    \begin{itemize}
    \tightlist
    \item
      Pt stable + no history of heart disease \(\rightarrow\) IV
      flecainide
    \item
      Structural / ischaemic heart disease \(\rightarrow\) IV amiodarone
    \end{itemize}
  \item
    DC cardioversion if drugs fail
  \end{itemize}
\item
  \textbf{Rate control}

  \begin{itemize}
  \tightlist
  \item
    \(\beta\)-blockers
  \item
    Digoxin
  \item
    Rate-limiting CCB: verapamil / diltiazem
  \end{itemize}
\item
  \textbf{Thromboprophylaxis:}

  \begin{itemize}
  \tightlist
  \item
    Oral Warfarin
  \item
    Target INR: 2.0-3.0
  \item
    Reduces risk of stroke by \(\frac{2}{3}\)
  \item
    Start 4wks before cardioversion, continue till 3mo after successful
    cardioversion
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{myocardial-infarction-1}{%
\section{Myocardial Infarction}\label{myocardial-infarction-1}}

\hypertarget{management-of-acute-mi}{%
\subsection{Management of acute MI}\label{management-of-acute-mi}}

\includegraphics[width=.7\textwidth]{../assets/MI-mx.png}

\pagebreak

\hypertarget{dermatology}{%
\chapter{Dermatology}\label{dermatology}}

\hypertarget{anatomy-and-physiology}{%
\section{Anatomy and physiology}\label{anatomy-and-physiology}}

\begin{itemize}
\tightlist
\item
  Layers of skin:

  \begin{itemize}
  \tightlist
  \item
    Epidermis: further layered into (from out\(\rightarrow\)in)

    \begin{itemize}
    \tightlist
    \item
      corneum
    \item
      lucidum
    \item
      granulosum
    \item
      spinosum
    \item
      basale
    \end{itemize}
  \item
    Dermis: contains

    \begin{itemize}
    \tightlist
    \item
      blood vessels
    \item
      nerves
    \item
      pilosebaceous units (hair follicle + sebaceous gland)
    \end{itemize}
  \item
    Subcutis: adipose
  \end{itemize}
\end{itemize}

\hypertarget{epidermal-appendages}{%
\subsection{Epidermal appendages}\label{epidermal-appendages}}

\begin{itemize}
\tightlist
\item
  Hair follicles:

  \begin{itemize}
  \tightlist
  \item
    phases of growth

    \begin{itemize}
    \tightlist
    \item
      anagen:

      \begin{itemize}
      \tightlist
      \item
        active growth
      \item
        lasts years in scalp hairs
      \end{itemize}
    \item
      catagen:

      \begin{itemize}
      \tightlist
      \item
        transitional
      \item
        lasts days (in scalp)
      \end{itemize}
    \item
      telogen:

      \begin{itemize}
      \tightlist
      \item
        resting
      \item
        lasts months (in scalp)
      \end{itemize}
    \end{itemize}
  \end{itemize}
\item
  Sebaceous glands

  \begin{itemize}
  \tightlist
  \item
    usually \emph{associated with a hair follicle}
  \item
    \(\fbox{androgens}\rightarrow\) \textbf{\(\uparrow\)}
    \(\fbox{sebum}\)
  \item
    \(\fbox{oestrogen}\rightarrow\) \textbf{\(\downarrow\)}
    \(\fbox{sebum}\)
  \end{itemize}
\item
  Sweat glands

  \begin{itemize}
  \tightlist
  \item
    innerved by \emph{sympathetic cholinergic} fibres
  \end{itemize}
\end{itemize}

\hypertarget{principles-of-management-of-skin-disease}{%
\section{Principles of management of skin
disease}\label{principles-of-management-of-skin-disease}}

\hypertarget{topical-treatments}{%
\subsection{Topical treatments}\label{topical-treatments}}

\begin{itemize}
\tightlist
\item
  Ointments vs Creams

  \begin{itemize}
  \tightlist
  \item
    Ointments preferred to creams for dry skin (e.g.~chronic eczema) as

    \begin{itemize}
    \tightlist
    \item
      more hydrating

      \begin{itemize}
      \tightlist
      \item
        80\% oil + 20\% water in ointments (vs 50-50 for creams)
        \(\rightarrow\) prevent water loss from skin by oil layer
      \end{itemize}
    \item
      less preservatives \(\rightarrow\) less risk of allergy
    \end{itemize}
  \end{itemize}
\item
  Emollients

  \begin{itemize}
  \tightlist
  \item
    Moisturise, lubricate, protect skin
  \item
    \emph{Vehicles without active drug}
  \end{itemize}
\item
  Gluocorticoids
\end{itemize}

\hypertarget{phototherapy}{%
\subsection{Phototherapy}\label{phototherapy}}

\begin{itemize}
\tightlist
\item
  \textbf{UVB}
\item
  \textbf{Psoralen UVA}

  \begin{itemize}
  \tightlist
  \item
    Psoralen:

    \begin{itemize}
    \tightlist
    \item
      natural photosensitiser from plant source
    \item
      cross-link DNA strands on excitation with UVA
    \end{itemize}
  \item
    Cumulative exposure to PUVA \(\rightarrow\;\;\uparrow\) risk of SCC,
    so reserved for UVB resistance
  \end{itemize}
\item
  Uses

  \begin{itemize}
  \tightlist
  \item
    Psoriasis
  \item
    Atopic eczema
  \item
    Vitiligo
  \item
    Chronic urticaria
  \end{itemize}
\end{itemize}

\hypertarget{systemics}{%
\subsection{Systemics}\label{systemics}}

\begin{itemize}
\tightlist
\item
  Antihistamines
\item
  \textbf{Retinoids}

  \begin{itemize}
  \tightlist
  \item
    \emph{Anti-inflammatory}
  \item
    Promote \emph{differentiation of skin cells}
  \item
    \textbf{Teratogenic}

    \begin{itemize}
    \tightlist
    \item
      must be prescribed with robust contraception
    \item
      females must have negative pregnancy test before, during, and
      after therapy
    \end{itemize}
  \end{itemize}
\item
  \textbf{Immunosuppressants}

  \begin{itemize}
  \tightlist
  \item
    Glucocorticoids e.g.~prednisolone
  \item
    Methotrexate
  \item
    Azathioprine
  \end{itemize}
\end{itemize}

\hypertarget{biologics}{%
\subsection{Biologics}\label{biologics}}

\begin{itemize}
\tightlist
\item
  Biological \emph{inhibitors} of \emph{proinflammatory cytokines}
\item
  \textbf{TNF-\(\alpha\) inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Infliximab
  \item
    Etanercept
  \end{itemize}
\item
  \textbf{Interleukin inhibitors}

  \begin{itemize}
  \tightlist
  \item
    Ustekinumab: IL-12, 23
  \item
    Guselkumab: IL-23
  \item
    Secukinumab: IL-17
  \end{itemize}
\item
  \emph{Rituximab}:

  \begin{itemize}
  \tightlist
  \item
    Binds to CD20 \(\rightarrow\) cause ADCC of B cells
  \item
    As terminally differentiated plasma cells don't have CD20 they're
    safe
  \item
    Use: pemphigus vulgaris
  \end{itemize}
\end{itemize}

\hypertarget{non-surgical-therapy}{%
\subsection{Non-surgical therapy}\label{non-surgical-therapy}}

\begin{itemize}
\tightlist
\item
  \textbf{Cryo}

  \begin{itemize}
  \tightlist
  \item
    \emph{Liquid N\(_2\)}
  \item
    Causes cell membrane destruction \(\rightarrow\) death
  \end{itemize}
\item
  Laser
\item
  PDT / photodynamic therapy
\end{itemize}

\hypertarget{skin-cancers}{%
\section{Skin cancers}\label{skin-cancers}}

\hypertarget{classification}{%
\subsection{Classification}\label{classification}}

\begin{itemize}
\tightlist
\item
  Non-melanoma skin cancer (NMSC): most common

  \begin{itemize}
  \tightlist
  \item
    SCC
  \item
    BCC
  \end{itemize}
\item
  Melanoma

  \begin{itemize}
  \tightlist
  \item
    Less common
  \item
    More metastatic risk \(\rightarrow\) cause of most skin cancer
    deaths
  \end{itemize}
\end{itemize}

\hypertarget{fungal-infections}{%
\section{Fungal infections}\label{fungal-infections}}

\hypertarget{types}{%
\subsection{Types}\label{types}}

\begin{itemize}
\tightlist
\item
  Superficial

  \begin{itemize}
  \tightlist
  \item
    Dermatophytes: aka \textbf{ringworm / tineasis}

    \begin{itemize}
    \tightlist
    \item
      \emph{Trichophyton}
    \item
      \emph{Epidermophyton}
    \item
      \emph{Microsporum}
    \end{itemize}
  \item
    Yeast
  \end{itemize}
\item
  Deep: less common

  \begin{itemize}
  \tightlist
  \item
    Chromomycosis
  \item
    Sporotrichosis
  \end{itemize}
\end{itemize}

\hypertarget{scabies}{%
\section{Scabies}\label{scabies}}

\hypertarget{agent}{%
\subsection{Agent}\label{agent}}

Caused by the mite \emph{Sarcoptis scabies hominis}

\hypertarget{diagnosis}{%
\subsection{Diagnosis}\label{diagnosis}}

\begin{itemize}
\tightlist
\item
  Identify the skin burrow
\item
  Visualize the mite by dermatoscope / extracting with a needle
\end{itemize}

\hypertarget{treatment}{%
\subsection{Treatment}\label{treatment}}

\begin{itemize}
\tightlist
\item
  Affected + all asymptomatic family members / physical contacts
\item
  Topical permethrin / malathion

  \begin{itemize}
  \tightlist
  \item
    2 applications
  \item
    1 wk apart
  \item
    Whole body, except head
  \end{itemize}
\item
  Oral Ivermectin:

  \begin{itemize}
  \tightlist
  \item
    Single dose
  \item
    For poor adherence, immunosuppresion or heavy infestation
  \end{itemize}
\end{itemize}

\hypertarget{acne}{%
\section{Acne}\label{acne}}

\begin{itemize}
\tightlist
\item
  \emph{Chronic inflammation} of \emph{pilosebaceous} units
\end{itemize}

\hypertarget{pathogenesis}{%
\subsection{Pathogenesis}\label{pathogenesis}}

Key components are:

\begin{itemize}
\tightlist
\item
  \(\uparrow\) Sebum production
\item
  Colonisation of pilosebaceous ducts by \emph{Propionibacterium acnes}
\item
  Occlusion of pilosebaceous ducts
\end{itemize}

\hypertarget{features}{%
\subsection{Features}\label{features}}

\begin{itemize}
\tightlist
\item
  Hallmark: \textbf{comedone}
\item
  Greasiness of skin
\end{itemize}

\hypertarget{management}{%
\subsection{Management}\label{management}}

\begin{itemize}
\tightlist
\item
  \textbf{Mild disease}

  \begin{itemize}
  \tightlist
  \item
    Topical Benzoyl peroxide
  \item
    Topical Retinoids
  \item
    Topical antibiotics

    \begin{itemize}
    \tightlist
    \item
      Erythromycin
    \item
      Clindamycin
    \end{itemize}
  \end{itemize}
\item
  \textbf{Moderate disease}: topical \emph{plus}

  \begin{itemize}
  \tightlist
  \item
    Systemic tetracycline
  \item
    Oestrogen containing OCP
  \item
    Isotretinoin: if inadequate response to topical+systemic therapy for
    6 months
  \end{itemize}
\item
  \textbf{Severe disease}

  \begin{itemize}
  \tightlist
  \item
    Isotretinoin 0.5-1 mg/kg for 4 months:

    \begin{itemize}
    \tightlist
    \item
      Reduce sebum secretion and follicle colonisation
    \item
      Teratogen
    \item
      Pregnancy must be avoided during treatment \emph{and} within 2 mo
      of drug cessation
    \end{itemize}
  \item
    Systemic glucocorticoid (with isotretinoin)
  \item
    If unable to use isotretinoin

    \begin{itemize}
    \tightlist
    \item
      UVB phototherapy
    \item
      PDT
    \end{itemize}
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{eczemas}{%
\section{Eczemas}\label{eczemas}}

\begin{itemize}
\tightlist
\item
  Seborrhoeic dermatitis is associated with \emph{Malassezia} yeasts
\end{itemize}

\hypertarget{features-1}{%
\subsection{Features}\label{features-1}}

Most types have the following clinical features:

\hypertarget{acute}{%
\subsubsection{Acute}\label{acute}}

\begin{itemize}
\tightlist
\item
  Ill-defined erythema, oedema
\item
  Papules, vesicles, bullae
\item
  Exudation
\item
  Scaling
\end{itemize}

\hypertarget{chronic}{%
\subsubsection{Chronic}\label{chronic}}

\begin{itemize}
\tightlist
\item
  Above features
\item
  Lichenification

  \begin{itemize}
  \tightlist
  \item
    Skin thickening with pronounced skin markings, 2\(^\circ\) to
    chronic scratching
  \item
    Fissures
  \item
    Dyspigmentation
  \end{itemize}
\end{itemize}

\hypertarget{management-of-eczema}{%
\subsection{Management of eczema}\label{management-of-eczema}}

\includegraphics[width=.8\textwidth]{../assets/eczema.jpg}

\pagebreak

\hypertarget{psoriasis}{%
\section{Psoriasis}\label{psoriasis}}

\begin{itemize}
\tightlist
\item
  Chronic inflammatory hyperproliferative skin disease
\item
  \textbf{Characteristics}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Well-defined erythematous scaly plaques}
  \item
    Affecting \textbf{extensor surfaces, scalp, nails}
  \end{itemize}
\end{itemize}

\hypertarget{histological-features}{%
\subsection{Histological features}\label{histological-features}}

\begin{itemize}
\tightlist
\item
  Keratinocyte hyperproliferation + abnormal differentiation
  \(\rightarrow\) nucleated stratum corneum cells (transit time from
  basale to corneum reduced to 5 from 28 \(\rightarrow\) keratinocytes
  reach the surface while immature)
\item
  Inflammation with Th-1 and Th-17 infiltration
\item
  Tortuosity of dermal capillaries and release of VEGF
\end{itemize}

\hypertarget{exacerbating-factors}{%
\subsection{Exacerbating factors}\label{exacerbating-factors}}

\begin{itemize}
\tightlist
\item
  \textbf{Sunlight}
\item
  \textbf{Trauma}
\item
  \textbf{Infection}

  \begin{itemize}
  \tightlist
  \item
    \(\beta\)-haemolytic strep \(\uparrow\) guttate psoriasis
  \item
    HIV may initally present with severe psoriasis
  \end{itemize}
\item
  \textbf{Drugs}

  \begin{itemize}
  \tightlist
  \item
    Antimalarials
  \item
    \(\beta\)-blockers
  \item
    Lithium
  \item
    NSAIDs
  \end{itemize}
\item
  \textbf{Stress and anxiety}
\end{itemize}

\hypertarget{clinical-types}{%
\subsection{Clinical types}\label{clinical-types}}

\begin{itemize}
\tightlist
\item
  \textbf{Plaque} psoriasis:

  \begin{itemize}
  \tightlist
  \item
    most common
  \item
    well-demarcated erythematous plaques
  \item
    silver-white scales in untreated

    \begin{itemize}
    \tightlist
    \item
      bleed on scraping (due to dilated vessels underneath)
      \(\rightarrow\) \textbf{Auspitz sign}
    \end{itemize}
  \item
    \textbf{Sites}

    \begin{itemize}
    \tightlist
    \item
      extensor surfaces

      \begin{itemize}
      \tightlist
      \item
        elbows
      \item
        knees
      \item
        lower back
      \end{itemize}
    \item
      scalp
    \item
      nails
    \end{itemize}
  \end{itemize}
\item
  \textbf{Guttate} psoriasis:

  \begin{itemize}
  \tightlist
  \item
    follows \emph{Strep} throat
  \item
    common in children/adolescent
  \item
    UVB highly effective
  \item
    may herald the onset of plaque psoriasis in adulthood
  \end{itemize}
\item
  \textbf{Erythrodermic} sporiasis: generalised \(\rightarrow\) medical
  emergency
\item
  \textbf{Pustular} psoriasis
\end{itemize}

\hypertarget{management-of-psoriasis}{%
\subsection{Management of psoriasis}\label{management-of-psoriasis}}

\includegraphics[width=.85\textwidth]{../assets/psoriasis.jpg}

\hypertarget{complications}{%
\subsection{Complications}\label{complications}}

\begin{itemize}
\tightlist
\item
  Psoriatic arthropathy
\item
  Exfoliative dermatitis
\item
  Secondary infection
\item
  Hyperuricaemia and gout
\end{itemize}

\pagebreak

\hypertarget{hypopigmentation}{%
\section{Hypopigmentation}\label{hypopigmentation}}

\hypertarget{causes-1}{%
\subsection{Causes}\label{causes-1}}

\begin{itemize}
\tightlist
\item
  Vitiligo
\item
  Albinism
\item
  Pityriasis alba
\item
  Pityriasis versicolor
\end{itemize}

\hypertarget{vitiligo}{%
\subsection{Vitiligo}\label{vitiligo}}

\begin{itemize}
\tightlist
\item
  \textbf{Acquired}
\item
  Cell-mediated \textbf{autoimmune destruction of melanocytes}
\item
  Loss of melanocytes \(\rightarrow\) hypopigmented patches
\end{itemize}

\hypertarget{albinism}{%
\subsection{Albinism}\label{albinism}}

\begin{itemize}
\tightlist
\item
  \textbf{Autosomal recessive}
\item
  \textbf{Reduced melanin production} by \textbf{normal number of
  melanocytes}
\item
  \(\uparrow\uparrow\) risk of sunburn, skin cancer
\end{itemize}

\hypertarget{hyperpigmentation}{%
\section{Hyperpigmentation}\label{hyperpigmentation}}

\hypertarget{causes-2}{%
\subsection{Causes}\label{causes-2}}

\begin{itemize}
\tightlist
\item
  \textbf{Endocrine}

  \begin{itemize}
  \tightlist
  \item
    Melasma/chloasma:

    \begin{itemize}
    \tightlist
    \item
      in pregnancy / some OCP users
    \item
      discrete patches of facial pigmentation
    \end{itemize}
  \item
    Addison's disease
  \item
    Cushing's syndrome
  \item
    Nelson's syndrome

    \begin{itemize}
    \tightlist
    \item
      hyper-ACTH 2\(^\circ\) to bilateral adrenalectomy for Cushing's
    \item
      due to loss of -ve feedback from plasma cortisol
    \end{itemize}
  \item
    CKD
  \end{itemize}
\item
  \textbf{Drugs}

  \begin{itemize}
  \tightlist
  \item
    Amiodarone
  \item
    Anti-cancers:

    \begin{itemize}
    \tightlist
    \item
      Bleomycin: Hodgkin's
    \item
      Busulfan: CML
    \end{itemize}
  \item
    Choroquine
  \item
    Psoralens
  \end{itemize}
\end{itemize}

\hypertarget{pseudorandom-factoids}{%
\section{Pseudorandom factoids}\label{pseudorandom-factoids}}

\hypertarget{spf-sun-protection-factor}{%
\subsection{SPF (sun protection
factor)}\label{spf-sun-protection-factor}}

\begin{itemize}
\tightlist
\item
  \(\frac{\LARGE{\text{UV dose for producing erythema with sunscreen}}} {\LARGE{\text{UV dose for producing erythema without sunscreen}}}\)
\end{itemize}

\hypertarget{mechanism-of-venous-ulceration}{%
\subsection{Mechanism of venous
ulceration}\label{mechanism-of-venous-ulceration}}

\begin{center}
\fbox{Incompetent valves} \\
$\downarrow$ \\
\fbox{$\uparrow$ capillary pressure} \\
$\downarrow$ \\
\fbox{Fibrinogen leaks out of capillary} \\
$\downarrow$ \\
\fbox{Forms fibrin clot around capillary (pericapillary cuffing)} \\
$\downarrow$ \\
\fbox{Impaired diffusion from capillaries} \\
$\downarrow$ \\
\fbox{Impaired oxygenation}
\end{center}

\pagebreak

\hypertarget{nephrology}{%
\chapter{Nephrology}\label{nephrology}}

\hypertarget{uti}{%
\section{UTI}\label{uti}}

\hypertarget{definition}{%
\subsection{Definition}\label{definition}}

Presence of \textgreater{} 10\(^5\) organisms/mL in a mid-stream sample
of urine.

\hypertarget{features-2}{%
\subsection{Features}\label{features-2}}

\begin{itemize}
\tightlist
\item
  \textbf{LUTI}: cystitis/urethritis

  \begin{itemize}
  \tightlist
  \item
    Frequency
  \item
    Urgency
  \item
    Dysuria (burning urethral pain during micturition)
  \item
    Haematuria
  \item
    Strangury (intense desire to pass more urine after voiding, due to
    spasm of inflamed bladder wall)
  \end{itemize}
\item
  \textbf{UUTI}: acute pyelonephritis

  \begin{itemize}
  \tightlist
  \item
    Fever with chills and rigor
  \item
    Vomiting
  \item
    Loin pain
  \item
    Renal angle tenderness
  \end{itemize}
\end{itemize}

\hypertarget{commonly-involved-pathogens}{%
\subsection{Commonly involved
pathogens}\label{commonly-involved-pathogens}}

\begin{itemize}
\tightlist
\item
  \emph{E. coli}: 75\%
\item
  \emph{Proteus}
\item
  \emph{Pseudomonas}
\item
  \emph{Streptococci}
\item
  \emph{Staph. epidermidis}
\end{itemize}

\hypertarget{investigations-1}{%
\subsection{Investigations}\label{investigations-1}}

\begin{itemize}
\tightlist
\item
  Dipstick test for nitrites, leucocyte esterase, and glucose

  \begin{itemize}
  \tightlist
  \item
    Most urinary pathogens (e.g.~\emph{E. coli, Proteus} etc) reduce
    nitrate to nitrite
  \item
    UTI \(\rightarrow\) Neutrophils in urine \(\rightarrow\) leucocyte
    esterase
  \end{itemize}
\item
  Microscopy for WBC and organisms
\item
  Urine culture
\end{itemize}

\hypertarget{treatment-1}{%
\subsection{Treatment}\label{treatment-1}}

\hypertarget{cystitis}{%
\subsubsection{Cystitis}\label{cystitis}}

\begin{itemize}
\tightlist
\item
  \textbf{1st choice}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Trimethoprim} (200mg bds 3 days)
  \item
    \textbf{Nitrofurantoin} (50mg qds 3 days)
  \end{itemize}
\item
  \textbf{Pregnancy}

  \begin{itemize}
  \tightlist
  \item
    Nitrofurantoin (50mg qds 7 days)
  \item
    Cefalexin (250mg qds 7 days)
  \end{itemize}
\item
  Avoid trimethoprim during pregnancy, and nitrofurantoin at term
\end{itemize}

\hypertarget{pyelonephritis}{%
\subsubsection{Pyelonephritis}\label{pyelonephritis}}

\begin{itemize}
\tightlist
\item
  \textbf{1st choice}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Cefalexin} (1g qds 14 days)
  \item
    \textbf{Ciprofloxacin} (500mg bds 7 days)
  \end{itemize}
\item
  Hospitalise if no response within 24h
\end{itemize}

\hypertarget{epididymo-orchitis}{%
\subsubsection{Epididymo-orchitis}\label{epididymo-orchitis}}

\begin{itemize}
\tightlist
\item
  \emph{1st choice}: Ciprofloxacin
\end{itemize}

\hypertarget{acute-prostatitis}{%
\subsubsection{Acute prostatitis}\label{acute-prostatitis}}

\begin{itemize}
\tightlist
\item
  \emph{1st choice}: Trimethoprim
\end{itemize}

\hypertarget{prophylactic-measures-in-women-with-recurrent-uti}{%
\subsection{Prophylactic measures in women with recurrent
UTI}\label{prophylactic-measures-in-women-with-recurrent-uti}}

\begin{itemize}
\tightlist
\item
  Fluid intake \(\ge\) 2L/day
\item
  Regular complete bladder evacuation
\item
  Emptying the bladder before and after intercourse
\item
  Good personal hygiene
\item
  Continuous prophylactic trimethoprim (100mg) and nitrofurantoin (50
  mg) at night
\end{itemize}

\pagebreak

\hypertarget{rheumatology}{%
\chapter{Rheumatology}\label{rheumatology}}

\hypertarget{investigations-of-musculoskeletal-disease}{%
\section{Investigations of musculoskeletal
disease}\label{investigations-of-musculoskeletal-disease}}

\hypertarget{joint-fluid-aspiration}{%
\subsection{Joint fluid aspiration}\label{joint-fluid-aspiration}}

\begin{itemize}
\tightlist
\item
  Normal:

  \begin{itemize}
  \tightlist
  \item
    Amount small
  \item
    Viscosity high
  \item
    Colourless / pale yellow
  \end{itemize}
\item
  Inflammation:

  \begin{itemize}
  \tightlist
  \item
    Amount raised
  \item
    Viscosity lowered (due to enzymatic degradation of hyaluronan \&
    aggrecan)
  \item
    Turbid (due to neutrophils)
  \end{itemize}
\item
  Crystal-induced arthropathies

  \begin{itemize}
  \tightlist
  \item
    Crystals seen by polarised light microscopy
  \item
    Urate crystals \(\rightarrow\) long, needle shaped, -ve
    birefringence
  \item
    Ca pyrophosphate crystals \(\rightarrow\) small, rhomboid, +ve
    birefringence \#\#\# Bone scintigraphy
  \end{itemize}
\item
  Dx of metastatic bone disease and Paget's
\item
  \(^99\)Tc radiolabelled bisphosphonate used
\end{itemize}

\hypertarget{dexa-dual-emission-x-ray-absorptiometry}{%
\subsection{DEXA (Dual Emission X-ray
Absorptiometry)}\label{dexa-dual-emission-x-ray-absorptiometry}}

\begin{itemize}
\tightlist
\item
  Measure BMD (bone mineral density)

  \begin{itemize}
  \tightlist
  \item
    \textless{} -2.5 \(\rightarrow\) osteoporosis
  \item
    Between -2.5 and -1 \(\rightarrow\) osteopoenia
  \item
    \textgreater{} 2.5 \(\rightarrow\) high bone mass (most common cause
    osteoarthritis)
  \end{itemize}
\end{itemize}

\hypertarget{immunology}{%
\subsection{Immunology}\label{immunology}}

\begin{itemize}
\tightlist
\item
  \textbf{RF}

  \begin{itemize}
  \tightlist
  \item
    Antibody to Fc fragment of human Ig
  \item
    70\% sensitive for RA (if nodules \& extra-articular manifestations
    then 100\% sensitive); specificity poor
  \item
    \textbf{RF +ve diseases}

    \begin{itemize}
    \tightlist
    \item
      Rheumatoid arthritis
    \item
      Sjogren's syndrome
    \item
      SLE
    \item
      Old age (\textgreater{} 65)
    \end{itemize}
  \end{itemize}
\item
  \textbf{ACPA}

  \begin{itemize}
  \tightlist
  \item
    Antibody to peptides in which arginine has been converted to
    citrulline by peptidylarginine deiminase, an enzyme abundant in
    inflamed synovium.
  \item
    70\% sensitive, \textgreater95\% specific for RA
  \end{itemize}
\item
  \textbf{ANA} (antinuclear antibodies)

  \begin{itemize}
  \tightlist
  \item
    100\% sensitive for SLE but poor specificity
  \item
    \textbf{ANA +ve diseases}

    \begin{itemize}
    \tightlist
    \item
      SLE
    \item
      Sjogren's
    \item
      Systemic sclerosis
    \item
      Rheumatoid arthritis
    \end{itemize}
  \end{itemize}
\item
  \textbf{Complement C3}

  \begin{itemize}
  \tightlist
  \item
    Active SLE \(\rightarrow\;\;\downarrow\) C3 (due to consumption of
    C3 by immune complexes)
  \end{itemize}
\end{itemize}

\hypertarget{seropositive-vs-seronegative-arthritis}{%
\section{Seropositive vs Seronegative
arthritis}\label{seropositive-vs-seronegative-arthritis}}

\begin{itemize}
\tightlist
\item
  Seropositive: RF+ inflammatory arthritis

  \begin{itemize}
  \tightlist
  \item
    Rheumatoid arthritis
  \item
    SLE
  \end{itemize}
\item
  Seronegative: RF- inflammatory arthritis

  \begin{itemize}
  \tightlist
  \item
    Ankylosing spondylitis
  \item
    Reactive arthritis
  \item
    Psoriatic arthropathy
  \end{itemize}
\end{itemize}

\hypertarget{osteoarthritis}{%
\section{Osteoarthritis}\label{osteoarthritis}}

\begin{itemize}
\tightlist
\item
  Characterised by

  \begin{itemize}
  \tightlist
  \item
    degeneration of articular cartilage
  \item
    subchondral osteosclerosis
  \item
    osteophyte formation at joint margin
  \item
    enlargement of affected joint
  \end{itemize}
\item
  Sites

  \begin{itemize}
  \tightlist
  \item
    hips
  \item
    knees
  \item
    PIPs
  \item
    DIPs
  \item
    cervical and lumbar spine
  \end{itemize}
\item
  Investigations:

  \begin{itemize}
  \tightlist
  \item
    X-ray of affected joint: findings described above in characteristics
  \item
    MRI spine if spine OA + suspected root compression / spinal stenosis
  \end{itemize}
\item
  Treatment

  \begin{itemize}
  \tightlist
  \item
    Conservative:

    \begin{itemize}
    \tightlist
    \item
      Wt loss
    \item
      Exercise
    \item
      NSAIDs
    \item
      Intraarticular glucocorticoids
    \end{itemize}
  \item
    Surgical: if refractory

    \begin{itemize}
    \tightlist
    \item
      Total joint replacement
    \item
      Osteotomy
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{spondyloarthropathies}{%
\section{Spondyloarthropathies}\label{spondyloarthropathies}}

\begin{itemize}
\tightlist
\item
  Asymmetrical oligoarthrites associated with HLA-B27 and typically
  involving the spine

  \begin{itemize}
  \tightlist
  \item
    Ankylosing spondylitis
  \item
    Reactive arthritis
  \item
    Psoriatic arthropathy
  \item
    Axial spondyloarthritis
  \item
    Entropathic spondyloarthritis (arthritis associated with IBD)
  \end{itemize}
\item
  Common features:

  \begin{itemize}
  \tightlist
  \item
    Asymmetric oligoarthritis
  \item
    Sacroilitis
  \item
    Enthesitis (inflammation where tendon attaches to bone)
  \end{itemize}
\end{itemize}

\hypertarget{reactive-arthritis}{%
\subsection{Reactive arthritis}\label{reactive-arthritis}}

\begin{itemize}
\tightlist
\item
  ``Reactive'' to certain infections e.g.~\emph{Chlamydia, Campylobacter
  Salmonella, Shigella}.
\item
  \textbf{Reiter's syndrome}:

  \begin{itemize}
  \tightlist
  \item
    Triad of \emph{can't see, can't pee, can't bend the knee}

    \begin{itemize}
    \tightlist
    \item
      \textbf{Conjunctivitis}
    \item
      \textbf{Urethritis}
    \item
      \textbf{Reactive arthritis}
    \end{itemize}
  \item
    Due to \emph{Chlamydia}
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{neurology}{%
\chapter{Neurology}\label{neurology}}

\hypertarget{raised-icp}{%
\section{Raised ICP}\label{raised-icp}}

\begin{itemize}
\tightlist
\item
  Normal ICP = \textbf{5-15 mmHg}
\end{itemize}

\hypertarget{causes-3}{%
\subsection{Causes}\label{causes-3}}

\begin{itemize}
\tightlist
\item
  \textbf{ICSOL}

  \begin{itemize}
  \tightlist
  \item
    Intracranial haemorrhage
  \item
    Tumours e.g.~glioma
  \item
    Brain abscess
  \end{itemize}
\item
  \textbf{Hydrocephalus}: blockade of CSF circulation

  \begin{itemize}
  \tightlist
  \item
    Obstructive / non-communicating
  \item
    Communicating
  \end{itemize}
\item
  \textbf{Cerebral oedema} e.g.~meningoencephilitis
\item
  \textbf{Venous sinus obstruction} e.g.~cerebral venous thrombosis
\end{itemize}

\hypertarget{features-3}{%
\subsection{Features}\label{features-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Headache}
\item
  \textbf{Vomiting}
\item
  \textbf{Diplopia / blurred vision}: Due to \emph{6th nerve palsy}

  \begin{itemize}
  \tightlist
  \item
    6th nerve palsy due to

    \begin{itemize}
    \tightlist
    \item
      stretching of the long, slender nerve
    \item
      compression against petrous temporal bone
    \end{itemize}
  \end{itemize}
\item
  \textbf{Papilloedema}
\item
  \textbf{Bradycardia}
\item
  \textbf{Hypertension}
\item
  \textbf{Depressed consciousness}
\end{itemize}

\hypertarget{management-1}{%
\subsection{Management}\label{management-1}}

\begin{itemize}
\tightlist
\item
  According to cause:

  \begin{itemize}
  \tightlist
  \item
    Mass lesion \(\rightarrow\) surgical decompression
  \item
    Hydrocephalus \(\rightarrow\) \emph{ventriculoperitoneal shunt}
    operation
  \item
    Oedema \(\rightarrow\) glucocorticoids
  \end{itemize}
\item
  Supportive:

  \begin{itemize}
  \tightlist
  \item
    Head elevation
  \item
    Fluid balance
  \item
    BP control
  \item
    Diuretics: mannitol
  \end{itemize}
\end{itemize}

\hypertarget{neurological-emergencies}{%
\section{Neurological emergencies}\label{neurological-emergencies}}

\begin{itemize}
\tightlist
\item
  \textbf{Status epilepticus}
\item
  \textbf{Stroke} (if thrombo)
\item
  \textbf{Subarachnoid haemorrhage}
\item
  \textbf{Cord compression}
\item
  \textbf{GBS}
\item
  \textbf{Myasthenia gravis} (if bulbar and/or respiratory)
\end{itemize}

\pagebreak

\hypertarget{status-epilepticus}{%
\section{Status epilepticus}\label{status-epilepticus}}

\hypertarget{definition-1}{%
\subsection{Definition}\label{definition-1}}

Continuous or recurrent \textbf{seizures} for \textbf{\(\ge\) 30 mins
without gain of consciousness} in between.

\hypertarget{management-2}{%
\subsection{Management}\label{management-2}}

\includegraphics[width=.7\textwidth]{../assets/stat-epi.png}

\hypertarget{all-jerks-root-values}{%
\section{All jerks root values}\label{all-jerks-root-values}}

\begin{itemize}
\tightlist
\item
  Biceps: C5
\item
  Supinator: C6
\item
  Triceps: C7
\item
  Finger (aka Hoffmann test): C8
\item
  Knee: L3, L4
\item
  Ankle: S1, S2
\item
  Plantar: S1 (technically not a jerk since it's a superficial reflex)
\end{itemize}

\pagebreak

\hypertarget{subarachnoid-haemorrhage}{%
\section{Subarachnoid haemorrhage}\label{subarachnoid-haemorrhage}}

\hypertarget{causes-4}{%
\subsection{Causes}\label{causes-4}}

\begin{itemize}
\tightlist
\item
  Ruptured berry aneurysm (85\%)
\item
  Arterio-venous malformations
\end{itemize}

\hypertarget{features-4}{%
\subsection{Features}\label{features-4}}

\begin{itemize}
\tightlist
\item
  Sudden severe ``thunderclap'' headache (often occipital)
\item
  Vomiting
\item
  High BP
\item
  Neck stiffness
\item
  May be loss of consciousness
\item
  Photophobia
\end{itemize}

\hypertarget{investigations-2}{%
\subsection{Investigations}\label{investigations-2}}

\begin{itemize}
\tightlist
\item
  CT scan: hyperdense material in the subarachnoid space
\item
  Lumbar puncture: blood, xanthochromia
\end{itemize}

\hypertarget{management-3}{%
\subsection{Management}\label{management-3}}

\begin{itemize}
\tightlist
\item
  \textbf{Nimodipine} 30-60mg IV for 5-14d, followed by 360mg oral for
  7d

  \begin{itemize}
  \tightlist
  \item
    \emph{prevents delayed ischaemia}
  \end{itemize}
\item
  Insertion of \textbf{Pt coils} into aneurysm
\item
  \textbf{Surgical clipping} of the neck of the aneurysm
\item
  Surgical removal if AVM
\end{itemize}

\pagebreak

\hypertarget{diabetes-mellitus}{%
\chapter{Diabetes Mellitus}\label{diabetes-mellitus}}

\hypertarget{mechanism-of-insulin-secretion}{%
\section{Mechanism of insulin
secretion}\label{mechanism-of-insulin-secretion}}

\includegraphics[width=.7\textwidth]{../assets/insulin-secr.jpg}

\hypertarget{incretin-effect}{%
\section{Incretin effect}\label{incretin-effect}}

For the same glucose load applied orally and IV, the oral load
stimulates more insulin secretion (because oral load \(\rightarrow\)
release of gut peptides GLP-1 and GIP \(\rightarrow\;\;\uparrow\)
insulin secretion).

\includegraphics[width=.5\textwidth]{../assets/incretin.png}

\hypertarget{diabetic-ketoacidosis-dka}{%
\section{Diabetic ketoacidosis (DKA)}\label{diabetic-ketoacidosis-dka}}

\begin{itemize}
\tightlist
\item
  \textbf{Medical emergency}
\item
  Cause of death

  \begin{itemize}
  \tightlist
  \item
    Children: cerebral oedema
  \item
    Adults:

    \begin{itemize}
    \tightlist
    \item
      \textbf{Hypokalaemia}
    \item
      ARDS
    \item
      Comorbidities: acute MI, sepsis, pneumonia
    \end{itemize}
  \end{itemize}
\item
  \textbf{Cardinal biochemical features}

  \begin{itemize}
  \tightlist
  \item
    Hyperglycaemia \(\rightarrow\) osmotic diuresis \(\rightarrow\)
    dehydration, dyselectrolytaemia
  \item
    Hyperketonaemia:

    \begin{itemize}
    \tightlist
    \item
      Insulin deficiency + elevated catecholamines \(\rightarrow\)
      unrestrained lipolysis to make FFA \(\rightarrow\) hepatic
      ketogenesis
    \end{itemize}
  \item
    Metabolic acidosis
  \end{itemize}
\end{itemize}

\hypertarget{clinical-features}{%
\subsection{Clinical features}\label{clinical-features}}

\begin{itemize}
\tightlist
\item
  \textbf{Symptoms}

  \begin{itemize}
  \tightlist
  \item
    Polyuria, thirst
  \item
    Weakness
  \item
    Nausea, vomiting
  \item
    Abdominal pain
  \item
    Blurred vision
  \end{itemize}
\item
  \textbf{Signs}

  \begin{itemize}
  \tightlist
  \item
    Dehydration
  \item
    Hypotension
  \item
    Tachycardia
  \item
    Air hunger / Kussmaul breathing (deep and sighing breathing)
  \item
    Acetone breath
  \item
    Delirium, drowsiness, coma
  \end{itemize}
\end{itemize}

\hypertarget{management-4}{%
\subsection{Management}\label{management-4}}

\begin{itemize}
\tightlist
\item
  \textbf{Establish IV access}
\item
  \textbf{Volume replacement: 0.9\% NaCl }

  \begin{itemize}
  \tightlist
  \item
    If systolic BP \(\ge\) 90mmHg: 1L over 1h
  \item
    Else: \(\frac{1}{2}\)L over 15mins \(\rightarrow\) reassess. If BP
    still \textless{} 90mmHg, repeat.
  \end{itemize}
\item
  \textbf{Insulin therapy}: \textbf{IV} 0.1 U/kg/h

  \begin{itemize}
  \tightlist
  \item
    Corrects hyperglycaemia \& acidosis
  \end{itemize}
\item
  \textbf{Monitor}

  \begin{itemize}
  \tightlist
  \item
    Every 1h:

    \begin{itemize}
    \tightlist
    \item
      capillary blood glucose and ketone
    \item
      vitals: pulse, BP, resp rate, O\(_2\) sat, urine output
    \end{itemize}
  \item
    Every 2h: Venous HCO\(_3^{-}\) and K\(^+\)
  \item
    Every 4h: Serum electrolytes
  \end{itemize}
\item
  If K\(^+\) is low, 40mmol/L KCl with normal saline
\end{itemize}

\hypertarget{hypoglycaemia}{%
\section{Hypoglycaemia}\label{hypoglycaemia}}

\hypertarget{features-5}{%
\subsection{Features}\label{features-5}}

\begin{itemize}
\tightlist
\item
  \textbf{Autonomic}

  \begin{itemize}
  \tightlist
  \item
    Sweating
  \item
    Trembling
  \item
    Palpitations
  \end{itemize}
\item
  \textbf{Neuroglycopoenic}

  \begin{itemize}
  \tightlist
  \item
    Delirium
  \item
    Drowsiness
  \item
    Speech difficulty
  \item
    Incoordination
  \end{itemize}
\end{itemize}

\hypertarget{management-5}{%
\subsection{Management}\label{management-5}}

\includegraphics[width=.7\textwidth]{../assets/hypogly.png}

\begin{itemize}
\tightlist
\item
  Oral fast-acting carbohydrate (10-15g) e.g.~glucose drink /
  confectionery / honey to buccal mucosa
\item
  Repeat capillary glucose measurement 10-15mins later

  \begin{itemize}
  \tightlist
  \item
    If still hypo, repeat upto 3 cycles
  \item
    Still hypo after 3 cycles \(\rightarrow\) glucagon 1mg IM
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{insulin-therapy}{%
\section{Insulin therapy}\label{insulin-therapy}}

\hypertarget{indications}{%
\subsection{Indications}\label{indications}}

\begin{itemize}
\tightlist
\item
  Type I DM
\item
  Type II DM not controlled by OHA
\item
  DIP / GDM
\item
  DKA
\item
  Hyperkalaemia
\end{itemize}

\hypertarget{preparations}{%
\subsection{Preparations}\label{preparations}}

\begin{itemize}
\tightlist
\item
  \textbf{Rapid-acting} (rapid=LAG-less)

  \begin{itemize}
  \tightlist
  \item
    Lispro
  \item
    Aspart
  \item
    Glulisine
  \end{itemize}
\item
  \textbf{Short-acting:} soluble/regular insulin
\item
  \textbf{Intermediate-acting:} Isophane (I for I)
\item
  \textbf{Long-acting}

  \begin{itemize}
  \tightlist
  \item
    Glargine (gLARGE-in)
  \item
    Detemir Route of administration: \textbf{subcutaneous}
  \end{itemize}
\end{itemize}

\hypertarget{oral-hypoglycaemic-agents}{%
\section{Oral Hypoglycaemic Agents}\label{oral-hypoglycaemic-agents}}

\begin{itemize}
\tightlist
\item
  \textbf{Biguanides}: Metformin

  \begin{itemize}
  \tightlist
  \item
    Insulin \emph{sensitiser}
  \item
    \textbf{Mechanism of action}

    \begin{itemize}
    \tightlist
    \item
      \(\downarrow\) hepatic glucose production (gluconeogenesis and
      glycogenolysis)
    \item
      \(\uparrow\) gut glucose uptake \& utilisation
    \item
      weak inhibitor of mitochondrial respiration \(\rightarrow\;\)
      \(\uparrow\) AMP, \(\downarrow\) ATP \(\rightarrow\;\;\uparrow\)
      glucose uptake utilisation etc.
    \end{itemize}
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Weight neutral
    \item
      Non-hypoglycaemic
    \item
      \emph{Lactic acidosis}
    \end{itemize}
  \end{itemize}
\item
  \textbf{Sulphonylureas}: Glibenclamide, Gliclazide, Glimepiride

  \begin{itemize}
  \tightlist
  \item
    Insulin \emph{secretagogue}
  \item
    \textbf{Mechanism of action:} Block K\(^+\) channel in
    \(\beta\)-cells \(\rightarrow\;\;\uparrow\) insulin secretion
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Wt gain
    \item
      Hypoglycaemia
    \end{itemize}
  \end{itemize}
\item
  \textbf{\(\alpha\)-glucosidase inhibitors:} Acarbose

  \begin{itemize}
  \tightlist
  \item
    \textbf{Mechanism of action}: delay absorption of carbs
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Non-hypoglycaemic
    \item
      Flatulence
    \item
      Bloating
    \item
      Diarrhoea
    \end{itemize}
  \end{itemize}
\item
  \textbf{Incretin-based therapies:}

  \begin{itemize}
  \tightlist
  \item
    \textbf{DPP-4 inhibitors:} Gliptins

    \begin{itemize}
    \tightlist
    \item
      \textbf{MoA}

      \begin{itemize}
      \tightlist
      \item
        DPP-4: breaks down GLP-1 \& GIP \(\rightarrow\) inhibit incretin
        effect
      \end{itemize}
    \end{itemize}
  \item
    \textbf{GLP-1 receptor agonists:} Exenatide, liraglutide
  \end{itemize}
\item
  \textbf{Thiazolidinediones:} Pioglitazone

  \begin{itemize}
  \tightlist
  \item
    \textbf{Mechanism of action}

    \begin{itemize}
    \tightlist
    \item
      PPAR-\(\gamma\) agonist \(\rightarrow\) enhance action of insulin
    \end{itemize}
  \item
    \textbf{Side effects profile}

    \begin{itemize}
    \tightlist
    \item
      Non-hypoglycaemic
    \item
      Wt gain (increase fat cells)
    \end{itemize}
  \end{itemize}
\item
  \textbf{SGLT-2 inhibitors:} empagliflozin, dapagliflozin

  \begin{itemize}
  \tightlist
  \item
    \textbf{MoA:} inhibit reabsorption of glucose in renal tubules
    \(\rightarrow\) 25\% of filtered glucose excreted
  \item
    Resulting glycosuria can lead to genital fungal infections
  \item
    Empagliflozin \(\rightarrow\) 35\% reduced mortality in heart
    failure
  \end{itemize}
\end{itemize}

\pagebreak

\hypertarget{diabetic-retinopathy}{%
\section{Diabetic retinopathy}\label{diabetic-retinopathy}}

\includegraphics[width=.8\textwidth]{../assets/diabetic-retino.png}

\pagebreak

\hypertarget{gastrointestinal-diseases}{%
\chapter{Gastrointestinal diseases}\label{gastrointestinal-diseases}}

\hypertarget{weight-loss}{%
\section{Weight loss}\label{weight-loss}}

\hypertarget{causes-5}{%
\subsection{Causes}\label{causes-5}}

\begin{itemize}
\tightlist
\item
  \textbf{Endocrine}

  \begin{itemize}
  \tightlist
  \item
    DM (more in type I)
  \item
    Thyrotoxicosis
  \item
    Addison's
  \end{itemize}
\item
  \textbf{GI}

  \begin{itemize}
  \tightlist
  \item
    Any cause of dysphagia e.g.

    \begin{itemize}
    \tightlist
    \item
      Stroke
    \item
      MS
    \item
      Ca oesophagus
    \item
      Achalasia cardia
    \item
      Plummer-Vinson syndrome (oesophageal webs+IDA)
    \end{itemize}
  \item
    Malabsorption syndrome

    \begin{itemize}
    \tightlist
    \item
      IBD
    \item
      Chronic pancreatitis (due to enzyme insufficiency)
    \item
      Coeliac disease
    \end{itemize}
  \end{itemize}
\item
  \textbf{Malignancies}
\item
  \textbf{Chronic infection}

  \begin{itemize}
  \tightlist
  \item
    TB
  \item
    AIDS
  \end{itemize}
\item
  \textbf{Psychological}

  \begin{itemize}
  \tightlist
  \item
    Depression
  \item
    Anorexia nervosa
  \item
    Bulimia nervosa
  \item
    Alcoholism
  \end{itemize}
\end{itemize}

\hypertarget{haematology}{%
\chapter{Haematology}\label{haematology}}

\hypertarget{chronic-myeloid-leukaemia-cml}{%
\section{Chronic myeloid leukaemia
(CML)}\label{chronic-myeloid-leukaemia-cml}}

Defining characteristic: \textbf{Philadelphia chromosome}

\begin{itemize}
\tightlist
\item
  Shortened \textbf{chr22} by \emph{reciprocal translocation} with
  \textbf{chr9}
\item
  Results in \textbf{BCR-ABL fusion gene}
\item
  BCR-ABL codes for a \textbf{tyrosine kinase} which influences cell
  proliferation and survival
\end{itemize}

\hypertarget{features-6}{%
\subsection{Features}\label{features-6}}

\begin{itemize}
\tightlist
\item
  Wt loss
\item
  Lethargy
\item
  Abdominal discomfort
\item
  Splenomegaly
\item
  Hepatomegaly
\end{itemize}

\hypertarget{phases}{%
\subsection{Phases}\label{phases}}

\begin{itemize}
\tightlist
\item
  Chronic
\item
  Accelerated
\item
  Blastic crisis
\end{itemize}

\hypertarget{investigations-3}{%
\subsection{Investigations}\label{investigations-3}}

\begin{itemize}
\tightlist
\item
  \textbf{CBC:} anaemia, leucocytosis
\item
  \textbf{PBF:}

  \begin{itemize}
  \tightlist
  \item
    Full range of granulocytic precursors, from \emph{myeloblasts} to
    \emph{mature neutrophils}.
  \item
    Predominant: neutrophils and myelocytes.
  \item
    Myeloblasts \textless{} 10\%.
  \end{itemize}
\item
  \textbf{Bone marrow examination: }

  \begin{itemize}
  \tightlist
  \item
    Hypercellular marrow
  \item
    \(\uparrow\) M/E ratio
  \item
    \(\downarrow\) erythrpoiesis
  \item
    \(\uparrow\) leucopoiesis
  \end{itemize}
\item
  \textbf{Chromosome analysis} to detect Ph chromosome
\end{itemize}

\hypertarget{management-6}{%
\subsection{Management}\label{management-6}}

\hypertarget{chronic-phase}{%
\subsubsection{Chronic phase}\label{chronic-phase}}

\begin{itemize}
\tightlist
\item
  \textbf{1st line: Tyrosine kinase inhibitors (TKIs):}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Imatinib}
  \item
    \textbf{Dasatinib}
  \item
    \textbf{Nilotinib}
  \item
    normalise blood count within a month, complete cytogenetic response
    (disappearance of Ph chr) within 6 months in 90\% patients. Resample
    bone marrow at 6mo to confirm. Thereafter monitor 3-monthly by
    RT-PCR for BCR-ABL mRNA transcripts.
  \end{itemize}
\item
  \textbf{Allogeneic HSC transplant:} if TKI fails
\item
  \textbf{Hydroxycarbamide}
\item
  \textbf{Interferon:} in pregnancy
\end{itemize}

\pagebreak

\hypertarget{nutritional-diseases}{%
\chapter{Nutritional diseases}\label{nutritional-diseases}}

\hypertarget{vitamins}{%
\section{Vitamins}\label{vitamins}}

\hypertarget{b_1-thiamin-deficiency}{%
\subsection{\texorpdfstring{B\(_1\) (thiamin)
deficiency}{B\_1 (thiamin) deficiency}}\label{b_1-thiamin-deficiency}}

\hypertarget{functions-of-thiamin}{%
\subsubsection{Functions of thiamin}\label{functions-of-thiamin}}

\begin{itemize}
\tightlist
\item
  Cofactor in different pathways of aerobic metabolism of glucose

  \begin{itemize}
  \tightlist
  \item
    decarboxylation of pyruvate to acetyl-coA (so bridge between
    glycolysis and Krebs)
  \item
    decarboxylation of \(\alpha\)-ketoglutarate to succinate in Krebs
  \end{itemize}
\end{itemize}

\hypertarget{features-7}{%
\subsubsection{Features}\label{features-7}}

\begin{itemize}
\tightlist
\item
  For its pivotal role in aerobic glucose meta, the largest blow is
  dealt to the tissues most dependent on glucose - the \textbf{brain}
  and the \textbf{heart}.
\item
  \textbf{Beri-beri}

  \begin{itemize}
  \tightlist
  \item
    \textbf{Dry:} Neurological beri-beri

    \begin{itemize}
    \tightlist
    \item
      Peripheral neuropathy
    \item
      Wrist/foot drop
    \item
      \textbf{Korsakoff's psychosis}
    \item
      \textbf{Wernicke's encephalopathy}
    \end{itemize}
  \item
    \textbf{Wet:} Cardiac beri-beri (wet as it causes generalised
    oedema)

    \begin{itemize}
    \tightlist
    \item
      Biventricular failure
    \item
      Generalised oedema
    \item
      Pulmonary oedema
    \end{itemize}
  \end{itemize}
\end{itemize}

\hypertarget{treatment-2}{%
\subsubsection{Treatment}\label{treatment-2}}

\begin{itemize}
\tightlist
\item
  Wet and Wernicke's should be treated by IV vit-B and C mixture
\item
  Korsakoff's: irreversible, nonresponsive to thiamin
\end{itemize}

\hypertarget{b_12-deficiency}{%
\subsection{\texorpdfstring{B\(_12\)
deficiency}{B\_12 deficiency}}\label{b_12-deficiency}}

\hypertarget{functions-of-b_12}{%
\subsubsection{\texorpdfstring{Functions of
B\(_12\)}{Functions of B\_12}}\label{functions-of-b_12}}

\begin{itemize}
\tightlist
\item
  Recycles folate \(\rightarrow\) essential for \textbf{cell division}
  (especially in RBC)
\item
  \textbf{Myelination}
\end{itemize}

\hypertarget{features-8}{%
\subsubsection{Features}\label{features-8}}

\begin{itemize}
\tightlist
\item
  Megaloblastic anaemia
\item
  \textbf{Neurologic features}

  \begin{itemize}
  \tightlist
  \item
    Peripheral neuropathy
  \item
    Autonomic neuropathy
  \item
    Optic atropy
  \item
    Subacute combined degeneration of spinal cord
  \end{itemize}
\end{itemize}

\backmatter
\end{document}
